(VCCEP) Tier 1 Pilot Submission for BENZENE - Tera

These findings illustrate examples of studies with sufficient power that discern age-related
differences, but did not find that the risk of AML was dependent on age. Currently available
scientific and medical literature describing chemotherapy-induced AML in children appears to
indicate that children are not more sensitive for developing AML following leukemogenic
chemical exposure.
PERCENT DEVELOPING t-AML
8%
6%
4%
2%
0%
2% (n=51)
Benzene VCCEP Submission
March 2006
6% (n=51)
6% (n=51)
162
6% (n=51)
7.5
AGE (years)
Figure 8.2: Percent of children who developed t-AML following treatment for ALL with
etoposide (adapted from Winick et al., 1993).
ABSOLUTE EXCESS RISK OF t-AML
7
6
5
4
3
2
1
0
2.6
4.0
6.5
0–4 5–9 >10
AGE (years)
Figure 8.3: Age dependency of absolute excess risk of developing t-AML following treatment
with alkylating agents. Adapted from Tucker et al. (1987)